Edgewise Therapeutics Inc. experienced a sharp market sell-off on Tuesday, with shares falling 25% after the company published top-line findings from its 12-week Phase 2 CIRRUS-HCM study of EDG-7500 in patients with both obstructive and nonobstructive hypertrophic cardiomyopathy (HCM).
The company described the results as positive, but the steep drop in the stock suggests investors weighed other considerations - including the crowded HCM treatment landscape and questions about how compelling the results are on a relative basis.
Study design and patient population
The CIRRUS-HCM trial enrolled a total of 53 patients over a 12-week period. Within the cohort, 20 patients had obstructive HCM and 33 had nonobstructive HCM. The trial assessed hemodynamic measures and biomarker responses, including changes in NT-proBNP, a peptide used to assess cardiac stress.
Key efficacy findings
- In the obstructive HCM subgroup, 90% of patients demonstrated improvement in hemodynamic measures.
- Also in that subgroup, 74% of patients either reached normalization of NT-proBNP or experienced at least a 50% reduction from baseline.
- Among patients with nonobstructive HCM, 88% achieved normalization of NT-proBNP or a reduction of at least 50% from baseline.
EDG-7500 is described by the company as an oral, selective cardiac sarcomere modulator engineered to slow early contraction velocity and enhance cardiac relaxation in symptomatic HCM patients.
Safety and exposure
Edgewise reported that EDG-7500 was generally well tolerated across the trial population, with nearly all adverse events characterized as mild to moderate. The company noted two new onset atrial fibrillation events; investigators concluded both events were unrelated to the study drug.
Importantly, the company stated there was no observed relationship between EDG-7500 exposure and left ventricular ejection fraction (LVEF), and no LVEF reductions below 50% were reported in the trial data.
Next steps
Based on the topline results, Edgewise said the data support progressing EDG-7500 into Phase 3 clinical development. The company indicated it is targeting initiation of the Phase 3 program in the fourth quarter of 2026.
The divergence between the company characterizing the outcome as positive and the market reaction highlights investor sensitivity to competitive positioning and data interpretation in small-cap biopharma stocks.